NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Checked against the public recordLast updated May 16, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Kiadis Pharma
- Interventions being studied
- Drug: NB1011
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced, recurrent, or metastatic solid tumors * TS overexpression (\> 4 by reverse transcription polymerase chain reaction \[RT-PCR\]) in archival and fresh samples * Suitable for experimental monotherapy * Measurable disease Exclusion Criteria: * Tumors that cannot be biopsied or with low level of TS expression * Requirement for concomitant anticancer therapy * Treatment with another investigational product within 30 days of study entry * Pregnant or lactating women * Active or uncontrolled serious bacterial, viral, fungal, or parasitic infection. * HIV infection * Clinically apparent meningeal or central nervous system (CNS) metastases or carcinomatous meningitis
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- USC Norris Comprehensive Cancer CenterLos Angeles, California
- University of MinnesotaMinneapolis, Minnesota
- Princess Margaret HospitalToronto, Ontario
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 16, 2022. Always confirm current availability with the study team.